Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
The Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza.
Journal: Contemporary clinical trials
Published: June 30, 2022
Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS).
Journal: Influenza and other respiratory viruses
Published: June 22, 2022
Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by Respiratory Intensity and Impact Questionnaire.
Journal: Influenza and other respiratory viruses
Published: August 11, 2021
Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza-Related Hospitalizations in Adults-A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study).
Journal: Open forum infectious diseases
Published: June 01, 2021
Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
Journal: The new microbiologica
Published: January 11, 2017
Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
Journal: Journal of viral hepatitis
Published: February 11, 2016
Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin.
Journal: Open forum infectious diseases
Published: December 24, 2015
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.
Journal: Antiviral therapy
Published: September 10, 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Journal: Hepatology (Baltimore, Md.)
Published: September 04, 2015
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Journal: Hepatology (Baltimore, Md.)
Published: September 04, 2015
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
Journal: Journal of gastroenterology and hepatology
Published: August 24, 2015
Last Updated: 09/26/2026